REFERENCES
- Calne RY, Rolles K, White DJ, . Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033–1036.
- Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–612.
- Rasucen LC, Solez K, Colvin R. Fibrosis and atrophy in the renal allograft: Interim report and new directions. Am J Transplant. 2002;2:203–206.
- Pascula M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–590.
- Ram Peddi V, Jensik S, Pescovitz M, . An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant. 2005;19:130–136.
- Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int. 2002;61:727–734.
- Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation. 2000;69:376–383.
- Kreis H, Oberbauer R, Campistol JM, . Rapamycinmune maintenance regimen trial. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809–817.
- Weber T, Abendroth D, Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: First clinical experience. Transpl Int. 2005;18(2):151–156.
- Morris RE, Cao W, Huang X, . Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and ballooninjured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc. 1995;27:430–431.
- Suzuki T, Kopia G, Hayashi S, . Stentbased delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–1194.
- Sayin B, Karakayali H, Colak T, . Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and adverse effect of sirolimus after conversion. Transplant Proc. 2009;41:2789–2793.
- Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 1875;2004(4):1869–1875.
- Citterlo F, Scata MC, Violi P, . Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc. 2003;35:1292–1294.
- Egidi MF, Cowan PA, Naseer A, Gaber AO. Conversion to sirolimus in solid organ transplantation: A single-center experience. Tranplant Proc. 2003;35(Suppl. 3):131–137.
- Schena FP, Pascoe MD, Alberu J, . Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–242.
- Boratynska M, Banasik M, Watorek E, . Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc. 2006;38(101):104.
- Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, . Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol. 2002;13:1365–1373.